DB PC RCT: Double-blind, placebo-controlled, randomized controlled trial; SB PC XO: Single-blind, placebo-controlled, crossover; Open UC: open untreated controls; SB HDC: Single-blind, house dust extract controlled; open ISC: open inhaled steroid controlled; AS-BHR: allergen-specific bronchial hyperreactivity; PEF: peak expiratory flow rate; NS-BHR: nonspecific bronchial hyperreactivity; TGV: thoracic gas volume; concealment of allocation: A) clearly adequate, B) unclear, C) inadequate, D) not used.
Immunotherapy in asthma: an updated systematic review
Article first published online: 9 OCT 2008
Volume 54, Issue 10, pages 1022–1041, October 1999
How to Cite
Abramson, M., Puy, R. and Weiner, J. (1999), Immunotherapy in asthma: an updated systematic review. Allergy, 54: 1022–1041. doi: 10.1034/j.1398-9995.1999.00102.x
- Issue published online: 9 OCT 2008
- Article first published online: 9 OCT 2008
- Accepted for publication 19 May 1999
- randomized controlled trials
Allergen-specific immunotherapy (“hyposensitization” or “desensitization”) has long been a controversial treatment for asthma. Although beneficial effects upon clinically relevant outcomes have been demonstrated in randomized controlled trials, there remains a risk of severe and sometimes fatal anaphylaxis. The recommendations of professional bodies have ranged from cautious acceptance (1) to outright dismissal (2). A recent WHO position paper, which has been endorsed by eight other international and national bodies, concluded that allergen immunotherapy was an effective treatment for patients with allergic asthma (3).
We have previously conducted a meta-analysis of 20 randomized controlled trials of allergen immunotherapy for asthma published between 1954 and 1990 (4). We subsequently conducted a systematic review for the Cochrane Collaboration, including a further 34 trials published between 1957 and 1997 (5). Both reviews concluded that subjects randomized to immunotherapy reported significantly fewer asthma symptoms, required significantly less asthma medication, and demonstrated both reduced nonspecific and reduced allergen-specific bronchial hyperreactivity (BHR) compared to those randomized to placebo.
During recent years, there has been increasing interest in new allergen vaccines and new methods of delivery including oral, sublingual, and inhaled immunotherapy. Recombinant peptides containing the relevant epitopes, but lacking the ability to cross-link IgE bound to mast cells, have been evaluated in clinical trials. Finally, the Cochrane Collaboration has standardized protocols for systematic reviews and improved the statistical software for performing meta-analysis. Thus, it was again opportune to update our systematic review of allergen-specific immunotherapy for asthma.
The objectives were as follows:
to identify as many as possible of the published ran-domized controlled trials of allergen-specific immuno-therapy for allergic asthma
to assess the methodological quality of these randomized controlled trials
to estimate the overall efficacy of allergen-specific immunotherapy upon asthma symptoms, medication requirements, lung function, nonspecific BHR, and allergen-specific BHR
to compare the efficacy in asthma of mite, pollen, and animal dander immunotherapy with extracts of other allergens.
This review was restricted to randomized controlled trials (RCTs), which provide the best evidence for the efficacy of any medical treatment (6). Only studies which focused upon asthma were included. Studies of immunotherapy for hay fever were considered only if the results for subjects with asthma were separately identified. For the purposes of this review, allergen-specific immunotherapy included the administration of extracts of house-dust mites, pollens, animal danders, or moulds; chemically modified allergoids; or antigen–antibody complexes. Only the subcutaneous route of administration was considered.
Placebo-controlled trials are methodologically stronger, although studies which have administered house dust or other relatively inactive antigenic preparations to the control group were also considered. Double-blind trials were preferred, but single-blind and open studies were also reviewed for possible inclusion.
At least one of the following clinical outcomes had to be reported:
asthma symptoms (including symptom scores)
asthma medication requirements (including medication scores)
lung function (including peak expiratory flow, FEV1, and thoracic gas volume)
nonspecific BHR (to histamine, methacholine, or acetylcholine)
Studies which reported only nonclinical outcomes such as allergen-specific IgE (by RAST or skin prick test) or other in vitro results were excluded.
Studies published in languages other than English were considered if the translated abstract indicated that the study was an RCT of allergen immunotherapy for asthma, and a translator was sought (see Acknowledgments).
MEDLINE searches were undertaken for 1966–98 for studies of immunotherapy and asthma. Review articles identified in this process were surveyed for additional and earlier citations. Dissertation abstracts and Current Contents were also searched to identify more recently published and unpublished studies.
A search was performed of the Asthma database maintained by the Cochrane Airways Group at St George's Hospital Medical School, London, UK. This database included all studies with the key words “Asthma” or “Wheez*” from the MEDLINE, EMBASE, and Cinahl databases, together with other studies identified by hand searching. A total of over 900 nonunique citations were identified with the key words “Immunotherap*”, “Hyposensiti*”, or “Desensiti*” and were examined for possible inclusion.
Inclusion of studies in the review was decided by a simple majority of all three reviewers, who independently read the Methods sections of papers identified by the search strategy and applied the stated criteria. Quality assessment was performed by two reviewers, who independently assessed the concealment of allocation by the guidelines of the Cochrane Collaboration and applied the scoring system of Jadad et al. (7).
The planned comparisons were as follows:
allergen immunotherapy vs placebo
allergen immunotherapy vs antigenically inactive control
house-dust extracts vs placebo
allergen immunotherapy vs untreated control
allergen immunotherapy vs inhaled steroid.
These comparisons were performed separately for each outcome, namely, asthma symptoms, medication, lung function, nonspecific BHR, and allergen-specific BHR, whenever the results were reported.
Outcome data were extracted and entered into RevMan, version 3.1.1 (Update Software, Oxford, 1998), for statistical analysis (8). Categorical outcomes were analysed as odds ratios (OR) and 95% confidence intervals (95% CI) calculated by Peto's method for individual studies. The odds ratio is simply the ratio between the immunotherapy and control groups for the odds of subjects being the same or worse to subjects being better after treatment. The convention of the Cochrane Collaboration is to consider odds ratios greater than 1.0 as indicating clinically undesirable outcomes (in this review, worse symptoms, increased medication, deteriorating lung function, and increased nonspecific and allergen-specific BHR).
Continuous outcomes (symptom and medication scores, lung-function parameters, and indices of nonspecific and allergen-specific BHR) were also extracted from tables of results. Where the results were presented only in graphs, these were digitized and then converted to numbers with Un-Scan-It v4.0 (Silk Scientific Corporation, Orem UT, 1996). Continuous outcomes were analysed as standardized mean differences (SMD). The SMD is a statistic which expresses the difference in means between immunotherapy and control groups in units of the pooled standard deviation. Although the Cochrane Collaboration currently favours the weighted mean difference, we chose the SMD because many studies measured the same outcomes on different scales.
Fixed effects models were generally used to obtain summary statistics for the overall efficacy of allergen immunotherapy upon both categorical and continuous outcomes, and chi-square tests were performed to assess heterogeneity between studies. In this context, a P value of <0.05 indicates significant differences between studies and raises the question of whether the results can be meaningfully combined. When significant heterogeneity was found, the overall efficacy was recalculated by random effects models, which provide more realistic estimates of the confidence intervals under these circumstances (9).
Description of studies
Sixty-two randomized controlled trials published in 67 papers between 1954 and 1998 were identified which satisfied the inclusion criteria. The methods, participants, allergens administered, and outcomes of the included studies are listed in Table 1. There were 28 studies report-ing immunotherapy for mite allergy, generally Dermatophagoides pteronyssinus or D. farinae, although Armentia Medina et al. (15) used extracts of the storage mite Lepidoglyphus destructor. Three early studies (10, 16, 75) used extracts of house dust, which has since generally been considered antigenically inactive. There were 15 studies of immunotherapy for pollen allergy, utilizing extracts of Bermuda grass, orchard grass/cocksfoot, timothy grass, velvet grass, sweet vernal grass, perennial ryegrass, or ragweed pollen. Nine studies reported immunotherapy for animal dander allergy, particularly to cats and dogs. Two studies utilized extracts of the mould Cladosporium, and five attempted simultaneous immunotherapy for multiple aeroallergens. Four studies from one group of investigators (43–46) used allergen–antibody complexes for immuno-therapy.
|Study (Ref.)||Methods||Participants, age||Allergen extracts||Outcomes||Quality|
|Aas (10)||DB PC RCT||80 asthma, 12–14 years||House dust||Symptoms, AS-BHR||4 A|
|Adkinson et al. (11)||DB PC RCT||121 asthma, 5–14 years||Multiple||Symptoms, medication, PEF||4 B|
|Alvarez Cuesta et al. (12)||DB PC RCT||28 asthma and rhinitis,||Cat||Symptoms, Medication,||3 B|
|15-28 years||NS-BHR, AS-BHR|
|Amaral Marques & Avila (13)||DB PC RCT||28 asthma, 12–55 years||Mite||Symptoms, medication||2 B|
|Armentia Medina et al. (14)||DB PC RCT||30 pollen-allergic,||Pollen||NS-BHR, AS-BHR||1 B|
|Armentia Medina et al. (15)||DB RCT||35 mite-allergic||Mite||Symptoms, medication,||4 B|
|British Tuberculosis Association (16)||DB PC RCT||96 asthma, mean 24 years||House dust||Symptoms, medication,||4 A|
|British Thoracic Association (17)||DB PC RCT||70 asthma||Mite||Symptoms, medication,||3 B|
|Baur (18)||SB PC XO RCT||39 asthma, 18–45 years||Multiple||AS-BHR||1 B|
|Bertelsen et al. (19)||Open UC RCT||27 asthma, 7–15 years||Cat/dog||AS-BHR||2 D|
|Bousquet et al. (20)||Open PC RCT||48 pollen-allergic,||Pollen||Symptoms, medication||1 D|
|Bousquet et al. (21)||DB PC RCT||30 asthma, 18–42 years||Mite||AS-BHR||2 A|
|Bousquet et al. (22)||Open UC RCT||215 asthma, 3–72 years||Mite||Symptoms, medication,||1 D|
|Bousquet et al. (23)||Mixed PC RCT||60 pollen-allergic,||Pollen||Symptoms, medication||2 A|
|Bousquet et al. (24)||DB PC RCT||57 pollen-allergic,||Pollen||Symptoms||3 A|
|Bruce et al. (25)||PC RCT||39 asthma||Pollen||Symptoms, AS-BHR||3 B|
|Buchanan et al. (26)||DB PC RCT||55 adult asthma||Mite||Symptoms, medication,||2 B|
|Cantani et al. (27)||DB PC RCT||20 asthma, 4–13 years||Multiple||Symptoms, medication,||2 A|
|Choovaravech (28)||SB HDC RCT||57 asthma||Mite||Symptoms, medication,||1 B|
|Mean 30.4 years||PEF|
|Creticos et al. (29)||DB PC RCT||77 adult asthma||Pollen||Symptoms, medication,||4 A|
|Mean 35.5 years||PEF, AS-BHR|
|D'Souza et al. (30)||DB PC RCT||91 asthma, >10 years||Mite||Symptoms, medication||4 B|
|Dolz et al. (31)||DB PC RCT||28 pollen-allergic,||Pollen||Symptoms, medication,||3 B|
|Dreborg et al. (32)||DB PC RCT||30 mould-allergic,||Mould||Symptoms, medication,||2 B|
|5–17 years||PEF, AS-BHR|
|Franco et al. (33)||DB PC RCT||49 asthma, mean age||Mite||Symptoms, medication,||1 B|
|24.5 years||PEF, NS-BHR|
|Frankland & Augustin (34)||DB PC RCT||200 pollen-allergic,||Pollen||Symptoms||3 B|
|Gaddie et al. (35)||DB PC RCT||55 asthma, 13–68 years||Mite||Symptoms, medication,||2 B|
|Haugaard & Dahl (36)||DB PC RCT||24 animal-allergic||Cat/dog||Symptoms, NS-BHR,||3 C|
|asthma, 13–48 years||AS-BHR|
|Hill et al. (37)||Open PC RCT||20 asthma, 9–14 years||Pollen||Symptoms, medication||1 D|
|Johnstone (38)||DB PC RCT||112 pollen-allergic||Pollen||Symptoms||1 C|
|Johnstone & Crump (39)||DB PC RCT||173 asthmatic children||Multiple||Symptoms||5 B|
|Johnstone & Dutton (40)||DB PC RCT||130 asthma, <16 years||Multiple||Symptoms||5 B|
|Kohno et al. (41)||Open UC RCT||16 asthma, 19–41 years||Mite||Symptoms, PEF,||2 D|
|Kuna et al. (42)||DB PC RCT||24 asthma||Pollen||Symptoms, FEV1,||3 A|
|Mean 27.2 years||NS-BHR|
|Machiels et al. (43)||DB PC RCT||39 asthma, 16–57 years||Mite||Symptoms, medication,||3 B|
|PEF, NS-BHR, AS-BHR|
|Machiels et al. (44)||DB PC RCT||30 pollen-allergic,||Pollen||Symptoms, medication||3 B|
|Machiels et al. (45)||DB PC RCT||51 pollen-allergic,||Pollen||Symptoms, medication||3 B|
|Machiels et al. (46)||DB PC RCT||39 asthma, 16–57 years||Mite||Symptoms, medication,||3 B|
|FEV1, NS-BHR, AS-BHR|
|Malling (47), Malling et al. (48, 49)||DB PC RCT||22 asthma, 16–60 years||Mould||Symptoms, medication,||4 B|
|Maunsell et al. (50)||DB HDC RCT||34 asthma, 16–56 years||Mite||Symptoms||2 B|
|Mosbech et al. (51–53)||DB PC RCT||46 asthma, 18–56 years||Mite||Symptoms, medication,||2 A|
|PEF, NS-BHR, AS-BHR|
|Newton et al. (54)||DB PC RCT||14 asthma, 18–44 years||Mite||Symptoms, medication,||3 B|
|Ohman et al. (55)||DB PC RCT||17 asthma, 22–48 years||Cat||Symptoms, PEF, NS-BHR,||3 A|
|Olsen et al. (56)||DB PC RCT||31 asthma, 18–64 years||Mite||Symptoms, medication,||5 A|
|PEF, FEV1, AS-BHR|
|Ortolani et al. (57)||DB PC RCT||15 asthma, 15–45 years||Pollen||Symptoms, AS-BHR||2 B|
|Paranos & Petrovic (58)||SB PC RCT||14 asthma, 20–40 years||Mite||Medication, PEF, FEV1||1 B|
|Pauli et al. (59)||DB PC RCT||18 asthma, 19–40 years||Mite||Symptoms, medication,||4 B|
|Pichler et al. (60)||DB PC RCT||30 asthma, 20–46 years||Mite||Symptoms, medication,||2 B|
|Price et al. (61)||DB PC RCT||25 asthma, 5–15 years||Mite||Symptoms, medication,||3 B|
|Reid et al. (62)||DB PC RCT||18 asthma, 20–39 years||Pollen||Symptoms, medication||4 A|
|Sabbah et al. (63)||DB PC RCT||52 asthma,||Mite||Symptoms, medication||2 B|
|mean 28.7 years|
|Shaikh (64)||Open ISC RCT||51 asthma, 22–36 years||Mite||Symptoms, medication,||3 D|
|Smith (65)||DB PC RCT||22 asthma, 11–48 years||Mite||Symptoms, medication,||3 B|
|Sundin et al. (66)||DB PC RCT||39 asthma, 8–47 years||Cat/dog||Symptoms,||3 B|
|Taylor et al. (67)||DB PC RCT||42 asthma, 6–15 years||Mite||Lung function, height and||2 B|
|weight, chest examination|
|Taylor et al. (68)||DB PC RCT||10 asthma, 20–43 years||Cat||NS-BHR, AS-BHR||4 B|
|Torres Costa et al. (69)||Open ISC RCT||22 asthma, 12–28 years||Mite||Symptoms, medication,||3 D|
|PEF, FEV1, NS-BHR|
|Valovirta et al. (70, 71)||DB PC RCT||27 asthma, 5–18 years||Dog||Symptoms, AS-BHR||3 A|
|van Bever & Stevens (72)||DB PC RCT||18 asthma, 7–22 years||Mite||NS-BHR, AS-BHR||3 B|
|van Metre et al. (73)||DB PC RCT||22 asthma, 21–52 years||Cat||NS-BHR, AS-BHR||3 B|
|Varney et al. (74)||DB PC RCT||28 asthma, 19–50 years||Cat||Symptoms, AS-BHR||3 B|
|Vooren (75)||DB PC RCT||12 asthma||House dust||Symptoms, medication,||3 B|
|Warner et al. (76)||DB PC RCT||51 asthma, 5–14 years||Mite||Symptoms, medication,||4 B|
A further 125 studies were excluded from this review (77–201). The most common but not mutually exclusive reasons for exclusion were as follows: 37 studies were not randomized (84, 86, 91, 93, 97, 98, 103, 105, 108, 114, 116, 120, 122, 123, 126, 130, 132, 133, 135, 140, 145, 146, 149, 151, 157, 159, 163, 164, 166, 176, 177, 180, 185, 189, 193, 194, 198), 25 studies were not controlled (87–89, 99, 101, 107, 115, 121, 128, 131, 134, 137, 140, 148–150, 155, 169, 172, 181, 184, 189, 195, 199, 201), 29 studies solely or predominantly involved subjects who had allergic rhinitis/conjunctivitis rather than asthma (77, 79, 80, 82, 85, 90, 94, 96, 100, 108–113, 117–119, 127, 130, 138, 139, 153, 158, 160, 161, 174, 176, 192), 13 studies did not report clinically relevant outcomes (81, 129, 134, 144, 152, 155, 165, 166, 173, 179, 190, 196, 200), and one study was not analysed by intention to treat (171).
We also identified 14 clinical trials of oral immunotherapy (92, 106, 124, 125, 139, 156, 158, 167, 170, 175, 186–188, 191), seven trials of inhaled or intranasal immunotherapy (79, 80, 95, 142, 143, 147, 183), nine trials of sublingual immunotherapy (78, 90, 102, 110, 154, 158, 162, 182, 197), and one trial of homoeopathic immunotherapy (168) which were beyond the scope of the present review. Finally, six abstracts (83, 104, 119, 136, 141, 178) contained insufficient information for further assessment.
Two studies included in our previous review were excluded after closer examination, as they did not meet all the inclusion criteria. The untreated controls in Murray et al. (149) were not randomly allocated and the “placebo” controls were contaminated by concurrent administration of pollen immunotherapy. The allocation of subjects to high- or low-dose immunotherapy by Tuchinda & Chai (189) was not randomized. A further 13 studies published before or during 1998 were considered for possible inclusion. Clarification was sought from the authors as to whether they had conducted randomized controlled trials, but no replies were received by the time of submission.
A key criterion for assessing the quality of randomized controlled trials for which there is evidence of a relationship to the potential for bias in the results is concealment of allocation after randomization to active treatment or control (6). For this review, concealment of allocation was assessed (Table 1) as clearly adequate (category A) in only 13 studies (10, 16, 21, 23, 24, 27, 29, 42, 51, 55, 56, 62, 70). The adequacy or otherwise of 40 studies could not be determined from the details published in the papers (category B) and further information was sought from the authors. Only two studies (36, 45) used a clearly inadequate method for concealment of allocation (category C). A further seven open studies did not use any concealment of allocation (category D).
The quality score developed by Jadad et al. (7) awarded points for randomization, double blinding, whether these methods were well described and appropriate, and whether withdrawals and dropouts were described. Only three studies (39, 40, 56) achieved the maximum possible score of five points. Eleven studies received four points, 24 received three points, 15 received two points, and nine received only one point for methodological quality (Table 1). There was a high level of agreement between reviewers, and differences were resolved by consensus.
Fifty-three studies were placebo-controlled trials of allergen-specific immunotherapy, two compared immuno-therapy with an antigenically inactive control (28, 50), three compared house dust with placebo (10, 16, 75), and three utilized untreated controls (19, 22, 41). Only one study directly compared immunotherapy with inhaled steroids (64), although Torres Costa et al. (69) administered inhaled beclomethasone to both the active treatment and control groups for the first 18 months.
The results of the individual placebo-controlled trials and combined effects for each outcome are presented in Figs. 1–10. Symptom scores were reported by 22 studies, although neither Dreborg et al. (32) nor Olsen et al. (56) published the standard deviations (SDs), thus preventing the calculation of the standardized mean difference (SMD) for these studies. The combined SMD for symptom scores after mite immunotherapy was –0.71 with a 95% confidence interval of –1.37 to –0.05, which excluded 0, thus indicating a significant reduction in asthma symptoms (Fig. 1). The combined SMD after pollen immunotherapy was –0.72 (95% CI –1.14 to –0.31) also indicating significant symptomatic improvement. However, there was no significant improvement after immunotherapy with cat, dog, or multiple allergen extracts. For all allergens combined, the SMD was –0.73 (95% CI –1.07 to –0.39), but there was significant heterogeneity between studies (χ2=86.2, P<0.0005), with three studies (11, 25, 37) not finding any reduction in symptoms.
Symptoms were simply reported as worse, the same, or improved in another 22 studies. The combined odds ratio (OR) was 0.26, with a 95% CI from 0.17 to 0.41, which excluded 1, again indicating that patients randomized to immunotherapy were significantly less likely to report a deterioration in asthma symptoms than those randomized to placebo (Fig. 2). There were significant homogeneous improvements after immunotherapy with extracts of pollen (OR 0.13, 95% CI 0.04–0.42), animal dander (OR 0.20, 95% CI 0.05–0.87), and other allergens (OR 0.17, 95% CI 0.09–0.32). Less improvement was seen after mite immunotherapy (OR 0.39, 95% CI 0.21–0.75), and there was significant heterogeneity between these studies (χ2=21.3, P<0.05). Although the results of studies of children were relatively homogeneous (data not shown), there was significant heterogeneity between the results of adult studies (χ2=40, P<0.001), two studies (17, 26) actually finding symptoms to be more likely in treated patients.
Asthma medication scores were reported by 13 studies, with Cantani et al. (27), Dreborg et al. (32), and Olsen et al. (56) failing to publish the SDs. The combined SMD was –0.71 (95% CI –1.09 to –0.32), indicating a significant reduction in medication after immunotherapy (Fig. 3). There was a large reduction after mite immunotherapy, although this was accompanied by significant heterogeneity (χ2=16.1, P<0.005). The reduction after pollen immunotherapy achieved statistical significance in a fixed effects model (SMD=–0.54, 95% CI –0.85 to –0.23). Medication requirements were simply reported as increased, unchanged, or decreased in 16 studies. The combined OR was 0.32 (95% CI 0.22–0.46), indicating that patients randomized to immunotherapy were significantly less likely to require increased medication than those randomized to placebo (Fig. 4). Although there was significant heterogeneity between the studies reporting medication scores (χ2=28.7, P<0.001), there was substantial homogeneity between the latter 15 studies.
Lung-function results were reported by 14 studies, with several studies failing to provide SDs for peak expiratory flow (32), FEV1 (35, 46), or thoracic gas volume (61, 76). There was no overall improvement in lung-function parameters after immunotherapy (Fig. 5), and there was marked heterogeneity in peak expiratory flow between studies (χ2=27.6, P<0.0005). Indeed, there was even a suggestion that FEV1 deteriorated after immunotherapy in a small study by Paranos & Petrovic (58), in which the baseline lung function of patients randomized to mite immunotherapy and placebo was poorly matched. Lung function was simply reported as worse, the same, or improved in seven studies. Although there was homogeneity between these studies and an overall trend against a deterioration in lung function after immunotherapy, this did not achieve statistical significance (Fig. 6).
Bronchial hyperreactivity (BHR)
Indices of nonspecific BHR were reported by 12 studies. There were significant improvements in PD20 FEV1 to methacholine challenge (SMD –0.30, 95% CI –0.54 to–0.05) and in PC35 sGaw to acetylcholine after immunotherapy with allergen–antibody complexes (43). The improvement in PC20 FEV1 to histamine challenge failed to achieve statistical significance in a random effects model. Although there was significant heterogeneity between the results of these studies (χ2=22.7, P<0.025), there was an overall reduction in nonspecific BHR after immunotherapy (SMD –0.48, 95% CI –0.81 to –0.14) (Fig. 7). Nonspecific BHR was simply reported as increased, unchanged, or reduced in five small studies. There was homogeneity between these studies, and the combined OR of 0.22 (95% CI 0.10–0.48) indicated that patients randomized to immunotherapy were significantly less likely to develop increased nonspecific BHR than those randomized to placebo (Fig. 8).
Indices of allergen-specific BHR (such as PD20 FEV1 to allergen challenge) were reported by 14 studies. There was homogeneity between these studies with an overall SMD of–0.70 (95% CI –0.91 to –0.48), indicating a significant reduction in allergen-specific BHR after immunotherapy (Fig. 9). The effect was most marked for mite immunotherapy (SMD –1.14, 95% CI –1.62 to –0.65), and similar for pollen (SMD –0.69, 95% CI –1.09 to –0.30) and animal dander (SMD –0.71, 95% CI –1.08 to –0.34), but not significant for other allergens. Allergen-specific BHR was simply reported as increased, unchanged, or reduced by 16 studies. There was homogeneity between studies, and the combined OR of 0.28 (95% CI 0.19–0.41) indicated that patients randomized to immunotherapy were significantly less likely to develop increased allergen-specific BHR (Fig. 10).
Because of the small number and disparate outcomes reported by the non-placebo-controlled randomized trials, only limited meta-analysis could be performed. Choovoravech (28) did not find a significant reduction in asthma symptoms comparing house-dust-mite (HDM) immunotherapy with house dust (SMD=–0.23, 95% CI–0.77 to 0.30). However, Maunsell et al. (50) did find that patients randomized to HDM were significantly less likely to report asthma symptoms than those randomized to house dust (OR=0.2, 95% CI 0.05–0.8). Choovoravech (28) did not find any significant reduction in asthma medications after immunotherapy (OR=0.5, 95% CI 0.15–1.7).
The three studies (10, 16, 75) which compared house-dust extracts with placebo found negative results for most outcomes. Subjects randomized to house dust were less likely to report worse asthma symptoms, but the combined effect did not achieve statistical significance (OR=0.45, 95% CI 0.14–1.4). In the British Tuberculosis Association (16) study, those randomized to house dust had minimal reduction in asthma medication (OR=0.76, 95% CI 0.27–2.2) and were marginally less likely to show deterioration in lung function (OR=0.79, 95% CI 0.3–2.1). However, Aas (10) found that asthmatic children randomized to house dust had significantly reduced allergen-specific BHR (OR=0.19, 95% CI 0.06–0.59).
On the other hand, studies with untreated controls reported strongly positive results of allergen immunotherapy. Both Bousquet et al. (22) and Kohno et al. (41) found that patients randomized to immunotherapy demonstrated a significant reduction in asthma symptoms (combined SMD=–2.5, 95% CI –3.0 to –2.0) and a significant improvement in lung function (combined SMD=–0.81, 95% CI –1.21 to –0.39). Bousquet et al. (22) also reported significantly reduced medication requirements in the immunotherapy group (SMD=–2.6, 95% CI –3.1 to 2.0). Finally, Bertelsen et al. (19) found that those randomized to immunotherapy were significantly less likely to develop increased allergen-specific BHR (OR=0.2, 95% CI 0.05–0.9).
The only trial to compare allergen immunotherapy directly with inhaled steroids (64) found that symptom scores and FEV1 improved more rapidly in the group randomized to budesonide. However, as no standard deviations were reported, it was not possible to calculate standardized mean differences. In any case, there were no other trials with which these results could be meaningfully combined.
This updated systematic review of allergen immunotherapy for asthma has identified an additional 10 randomized controlled trials which were not covered by our previous review of studies published up to 1997 (5). Most of the studies not previously included were published during or after 1997. Two trials which were included in the previous review were excluded on this occasion after closer examination revealed that they did not meet all the inclusion criteria. A total of 125 studies were excluded from the review, mainly because they were not randomized, not controlled, did not report clinically relevant outcomes, or involved only subjects with allergic rhinoconjunctivitis.
Given the well-recognized bias for the publication of positive studies, it is quite possible that some additional negative studies have been conducted, but that their results have not been published in the medical literature. This problem could be avoided in the future by prospective registration of all clinical trials of allergen immunotherapy, as has been attempted in other clinical disciplines. Unfortunately, the concealment of allocation after randomization could not be clearly determined from the information presented in most of the papers. We would encourage authors of future papers to follow the CONSORT guidelines (202) and fully report such details. However, there was no obvious relationship between concealment or methodological quality and the findings of individual RCTs of immunotherapy.
This meta-analysis has confirmed that allergen-specific immunotherapy can significantly reduce asthma symptoms and medication requirements. The heterogeneity of symptom and medication scores is likely to have arisen from the different scoring schemes used in different studies. The heterogeneity of symptom scores remained significant after stratifying for the allergen administered. All but one study (23) combined both symptomatic and anti-inflammatory medications into a single score. We have previously criticized this approach (203), as changes in bronchodilator requirements could be obscured by changes in inhaled corticosteroid therapy. Standardization of asthma symptom and medication scores is required for easier interpretation of future studies. However, we do not believe that the heterogeneity of the results means that the studies should not be combined at all or that it invalidates the conclusions.
Medication requirements which were reported as categories, in contrast to the analysis using medication scores, showed significant homogeneity. We believe that this finding can translate into a clinically useful outcome, as one of the principal aims of attempting allergen immuno-therapy is to decrease medication requirements. While inhaled corticosteroid therapy remains the mainstay of asthma management, any reduction in this type of treatment while maintaining good asthma control would be welcome.
There was no consistent effect of immunotherapy upon lung function. The marked heterogeneity may have arisen from attempting to combine such diverse measures of lung function as FEV1, peak expiratory flow, and thoracic gas volume. These parameters presumably reflect different aspects of the pulmonary pathophysiology of asthma, such as reduced airway calibre, variable airflow limitation, and hyperinflation. However, significant heterogeneity remained after stratifying the analysis for each parameter. In contrast, our first meta-analysis (4) did find a modest improvement in lung function. However, in retrospect, this conclusion resulted substantially from the retrospective exclusion of one negative study (61) in response to a reviewer's concerns.
Patients randomized to immunotherapy were significantly less likely to develop increased nonspecific BHR, and there were modest improvement indices of nonspecific BHR. Homogeneity was achieved by stratifying the meta-analysis for each index of nonspecific BHR: PD20 FEV1 to methacholine, PC20 FEV1 to histamine, and PC35 sGaw to acetylcholine. Since indices of BHR are generally considered to follow a log normal distribution, the means and standard deviations of logPD20 were entered into RevMan to calculate the SMD.
Allergen immunotherapy significantly reduced allergen-specific BHR. Homogeneity was achieved by stratifying the meta-analysis for the allergen administered and expressing the results as logPD20. It would be desirable for future studies to use a standardized protocol for bronchial allergen challenges and to report the results in a more consistent fashion. Not surprisingly, it would appear that allergen immunotherapy has a greater effect upon allergen-specific BHR than upon nonspecific BHR.
The finding that allergen immunotherapy significantly and homogeneously improves allergen-specific bronchial BHR is clinically important. Patients with brittle extrinsic (allergic) asthma are at risk of sudden deterioration when exposed to increased levels of an aeroallergen to which they are sensitive. Any intervention which reduces the risk of an acute episode of asthma under these circumstances would be clinically useful. Currently, the measurement of allergen-specific BHR is the only accurate method of assessing such a risk.
Less importance should be attached to the results of the relatively small number of non-placebo-controlled trials. There is some evidence that HDM extracts may reduce asthma symptoms and allergen-specific BHR compared to house-dust extracts. One study even suggested that house-dust extracts alone could reduce allergen-specific BHR, challenging the view that such extracts are antigenically inactive. However, taken together, these results are consistent with the greater efficacy of HDM extracts compared with placebo. Studies with untreated controls are particularly susceptible to bias and may overestimate the true benefit of treatment. The effects of immunotherapy upon symptoms, medication, and lung function found in such studies are beyond the upper confidence limits for placebo-controlled studies.
The results of this systematic review are consistent with our previous meta-analyses (4, 5), and, importantly, the positive findings have not been overturned by the inclusion of additional randomized controlled trials. If anything, the combined effects of allergen immunotherapy upon symptom and medication scores are greater than previously estimated. In this review, greater control of heterogeneity was achieved with stratification by allergen and calcu-lation of combined effects by random rather than fixed effects models. The effects on all other outcomes were unchanged.
None the less, there are still some limitations to the present review. None of the studies included any data relating to asthma exacerbations, emergency room visits, or hospital admissions. Such unstable patients are rarely included in clinical trials, especially those of allergen immunotherapy. The safety of immunotherapy, particularly the occurrence of major systemic reactions, lies beyond the scope of the present review. Rare side-effects are often not adequately assessed in reports of clinical trials (4) and are better captured by schemes reporting adverse reactions. A narrative review by Lockey (204) identified 27 fatal anaphylactic reactions over a 6-year period (1985–91) during which up to 10 million allergen injections were administered annually in the USA. The mean rate of systemic reactions was 1/200 injections.
This report confirms the efficacy of immunotherapy; in particular, we emphasize the clinically useful outcomes of decreased medication requirements and improved allergen-specific BHR. Not only did these two outcomes show statistically significant improvement, but also the results were homogeneous. We believe that a reduction in medication and decreased allergen-specific BHR are clinically important findings and can lead to improved asthma control.
These results give no direct guidance concerning the clinical application of allergen immunotherapy. We have previously stated the well-accepted principles that we follow in using immunotherapy in asthma (4). These issues are discussed more fully in a joint position statement of the Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy (205) and the WHO position paper (3). We fully endorse these position papers and recommend that interested readers refer to them.
However, certain questions remain to be answered. What are the most important determinants of the clinical relevance of an allergen? Which patient is the ideal recipient of immunotherapy? Is the result better when there is a narrow range of positive skin tests, or is it just as effective in panreactors? Is monocomponent immunotherapy better than the use of multiple allergens to which the patient reacted? What is the optimal length of treatment and the best duration of effect? How does the cost-effectiveness of immunotherapy compare to new pharmacologic treatments for asthma? Some of these questions may be answered in the studies currently available, but others will require new and better designed randomized controlled trials.
We thank Daniel Czarny, Rosa Dias Santilhiano, Andrei Saramovich, Fiona Savio, Georg Schäppi, Noortje Hamse, Brechje Gosens, and Paul Angel for their assistance in translating studies published in languages other than English. The German Assistant™ (Microtac software) was used to translate papers published in German. David Hill kindly gave us access to the original data from his randomized controlled trial of grass pollen immunotherapy in children with asthma. Jean Bousquet provided unpublished methodological details about the trials conducted by his research group. The Cochrane Airways Group database was searched by Steve Milan and Anna Bara. David Badger and Vivienne Moore from the Australasian Cochrane Centre and Anna Bara gave advice on the use of RevMan. Peter Gibson and Paul Jones provided helpful comments on a previous version of this review.
- 3Allergen immunotherapy – therapeutic vaccines for allergic diseases. Allergy 1998;53 Suppl 44:4–42, , .
- 5Allergen specific immunotherapy for asthma (Cochrane Review)In: Cochrane Library, Issue 3 1998. Oxford: Update Software, , .
- 8User guide for Review Manager (RevMan). Version 3.1 for Windows Cochrane Collaboration, 1997, , , .
- 26A double blind controlled trial of Bencard house dust mite (Migen) hyposensitization in Zambian asthmatics. Med J Zambia 1981;15:14–16, , .
- 42The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol 1989;83:816–824, , , .
- 83Hyposensitization with Dermatophagoides pteronyssinus tyrosine absorbate in bronchial asthma. Allergol Immunopathol (Madr) 1980;8:351–352, , , .
- 84Double blind trial of hyposensitization to Dermatophagoides farinae and D. pteronyssinus in asthmatic children. Allerg Immunol (Paris) 1981;13:16–19, , , et al.
- 85Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. II. Efficacy of a double blind placebo controlled specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991;88:43–53, , , et al.
- 91Immunotherapy with pollens and fungi. Immunol Allergy Clin North Am 1992;12:39–52, .
- 98Immunotherapy with a standardised Dermatophagoides pteronyssinus glutaraldehyde modified extract against an unmodified extract: a comparative study of efficacy, tolerance and in vivo and in vitro modification of parameters. J Investig Allergol Clin Immunol 1995;5:325–332, , , et al.
- 101Randomized double-blind trial of a combination of cromoglycate disodium administration and specific desensitization treatment in adults with perennial extrinsic asthma and nonspecific bronchial hyperreactivity. Lotta Contro la Tuberculosi e le Malattie Polmonari Sociali 1988;58:658–663, , , et al.
- 104Effects of immunotherapy on specific and nonspecific sensitivity of the airways. J Allergy Clin Immunol 1984;73:140, , , , .
- 105Immunotherapy in infantile asthma. Pediatr Integral 1997;2:397–404, , .
- 119Immunotherapy as preventive allergy treatment. J Allergy Clin Immunol 1996;97:232, , , et al.
- 123Effectiveness of the specific hyposensitization of children with allergoses using a peroral vaccine from house dust. Pediatr Akusherstvo Ginekologiia 1979;3:5–7, .
- 126Hyposensitising (immunising) injections in hay fever and asthma. Pediatr Clin North Am 1959;6:698–708.
- 130Clinical and immunological effects of immunotherapy with glutaraldehyde modified house dust mite extract. Allergol Immunopathol (Madr) 1994;22:226–232, , , .
- 131Bronchial asthma. Clinical evolution with hyposensitization. Anales Espanoles Pediatr 1980;13:87–100, , .
- 138A multiclinic trial with glutaraldehyde-modified tyrosine-adsorbed ragweed pollen immunotherapy (pollinex(R)). Curr Ther Res 1981;29:745–756, , , et al.
- 141Immunotherapy with mPEG modified and unmodified D. pteronyssinus extract. Clinical results in a one year double-blind study. Ann Allergy 1985;55:389, , , et al.
- 146Immunotherapy – methods of treatment and results in children. Allergol Immunopathol (Madr) 1981;(Suppl 9):171–173.
- 154Sublingual immunotherapy in the treatment of allergic asthma in children: a controlled study. Riv Ital Pediatr 1991;17:75–78, , , , , .
- 161Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988;43:353–362, , , et al.
- 167Comparative study on the immunological and clinical efficacy of oral and subcutaneous hyposensitization. Allergologie 1980;3:101–106, , , .
- 168Is homoeopathy a placebo response? A controlled trial of homoeopathic immunotherapy (HIT) in atopic asthma. Complementary Ther Med 1993;1:24–25, , , et al.
- 178The mechanisms and clinical evaluation of allergen specific immunotherapy in patients with asthma. Respirology 1998;3(Suppl):A69.
- 184Effect of single allergen immunotherapy on early skin reactivity, symptom scores and total IgE levels in grass pollen allergics. Deri Hastaliklari Ve Frengi Arsivi 1998;32:164–170, , .
- 197Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53:662–672, , , et al.
- 205Specific allergen immunotherapy for asthma: a position paper of the Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy. Med J Aust 1997;167:540–544